



Pharmacy and Therapeutics Committee

October 12, 2017 12:00pm -5:00 pm
Gold Room, 3rd Floor
701 E. Jefferson Phoenix, AZ 85034

AGENDA

Teleconference: 1-877-820-7831 Passcode: 960711

Agenda Topics

Noon

Welcome and Introductions: Sara Salek, MD, Chief Medical Officer, AHCCCS

- July 10, 2017 P&T Minutes Review and Vote
- P&T Membership Update for 2018 to 2020
- Hemophilia Update

AHCCCS and Behavioral Health Drug Lists

12:15

Supplemental Rebate Class Review:

1. Hepatitis C Agents
 - a. Clinical review: Rick Pope: Provider Synergies
 - b. Pharma Testimony:
 - i. Laura Hill: Abbvie
 1. Viekira
 2. Technivie
 3. Mavyret
 - ii. Coleen Fong: Gilead Sciences
 1. Epclusa
 2. Harvoni
 3. Sovaldi
 4. Vosevi
 - c. Public Testimony:
 - i. Richard Manch, MD
2. Cytokine and CAM Inhibitors
 - a. Clinical review: Rick Pope: Provider Synergies
 - b. Pharma Testimony:
 - i. Jon Glover: Pfizer – Xeljanz/Xeljanz XR
 - ii. Melissa Walsh: Novartis – Cosentyx
 - iii. Alan Bakst: UCB - Cimzia
 - c. Public Testimony:
3. Long Acting Analgesic Narcotics
 - a. Clinical review: Rick Pope: Provider Synergies
 - b. Pharma Testimony:
 - i. Jon Glover: Pfizer – Embeda
 - ii. Michael DeGeorge: Collegium Pharmaceutical – Xtampza ER
 - c. Public Testimony: None
4. Growth Hormone
 - a. Clinical review: Rick Pope: Provider Synergies
 - b. Pharma Testimony:
 - i. Jignesh Patel: Novo Nordisk – Norditropin Flex Pro
 - ii. Jon Glover: Pfizer - Genotropin
 - c. Public Testimony: None

2:15	<p>5. Self-Injected Epinephrine</p> <ol style="list-style-type: none"> a. Clinical review: Rick Pope: Provider Synergies b. Pharma Testimony: c. Public Testimony: None <p>6. Inhaled Antibiotics</p> <ol style="list-style-type: none"> a. Clinical review: Rick Pope: Provider Synergies b. Pharma Testimony: c. Public Testimony: None <p>7. Progestational Agents</p> <ol style="list-style-type: none"> a. Clinical review: Rick Pope: Provider Synergies b. Pharma Testimony: c. Public Testimony: None <p><u>Executive Session</u></p> <p>Supplemental Rebate Class Discussions:</p> <ol style="list-style-type: none"> 1. Hepatitis C 2. Cytokine and CAM Antagonists 3. Long Acting Analgesic Narcotics 4. Growth Hormone 5. Inhaled Antibiotics 6. Self-Injected Epinephrine 7. Progestational Agents
3:45	<p>Break</p> <p>Public Therapeutic Class Votes</p>
4:00	<p>Biosimilar Update:</p> <ol style="list-style-type: none"> 1. etanercept-szszs - Erelzi - Enbrel 2. adalimumab-atto – Amjevita – Humira 3. Remicade <ol style="list-style-type: none"> a. Inflectra b. Renflexis
4:15	<p>New Drug Reviews: Non-Supplemental Rebate Class: <i>Suzi Berman, AHCCCS</i></p> <ol style="list-style-type: none"> 1. Haegarda 2. Baxdela 3. Trulance 4. Tymlos
5:00	<p>Meeting Adjourned</p>

2018 Meeting Dates:

- **January 16, 2018**
- **April 17, 2018**
- **July 17, 2018**
- **October 22, 2018**